6 citations
,
December 1996 in “The Journal of Clinical Pharmacology” Terazosin and finasteride together cause no major issues.
November 2003 in “PubMed”
January 2019 in “Actas urológicas españolas” Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
21 citations
,
October 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
August 2003 in “药物不良反应杂志” Combining finasteride and terazosin can cause severe allergic reactions.
11 citations
,
January 1995 in “Biomedicine & pharmacotherapy” TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
March 2005 in “The Nurse Practitioner” March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
1 citations
,
December 2005 in “The Journal of Urology” Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
6 citations
,
November 1998 in “The Journal of Clinical Pharmacology” Finasteride interacts with terazosin, but not doxazosin; caution needed.
April 2022 in “Reactions Weekly” January 2004 in “Actualidad en farmacología y terapéutica” Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.
March 2023 in “The Journal of Urology” Men with better urinary symptoms have a lower risk of death.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
22 citations
,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
September 2004 in “Inpharma Weekly” March 2005 in “Current Prostate Reports” 408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
14 citations
,
January 2020 in “Archivio Italiano di Urologia e Andrologia” Finasteride helps with prostate symptoms but may cause sexual side effects.
12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
5 citations
,
July 2008 in “The Journal of Urology” 20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
November 2005 in “The Journal of Urology” January 2016 in “The Korean Journal of Internal Medicine” Doxazosin may cause breast enlargement and pain in men.
13 citations
,
August 2013 in “Journal of pharmaceutical sciences” Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
April 2017 in “The Journal of Urology” Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
98 citations
,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.